XXII ASSEMBLEA MaNGO MILANO XXII ASSEMBLEA MANDO MILANO XXII ASSEMBLEA AND NEW DIRECTIONS IN GYNAECOLOGICAL CANCERS

MILANO June 26th-29th, 2025

Responsabili Scientifici: NICOLETTA COLOMBO, FRANCESCO RASPAGLIESI

New Endometrial Cancer Guidelines ESGO/ESTRO/ESP 2025: Medical perspective

Angelica Sikokis

Azienda Ospedaliero-Universitaria di Parma

Oncologia Medica




- Consulting/Advisory Board: AstraZeneca, Clovis Oncology, Eisai
- Lecture Fees: AstraZeneca, PharmaMar, GSK
- Travel Grants: AstraZeneca, GSK





What's new for Adjuvant Setting?






- Immunohistochemistry for p53 & mismatch repair proteins
- DNA sequencing for POLE exonuclease domain mutations

Kandoth et al, Nature 2013; Stelloo et al, Clin Cancer Research 2016 ; Talhouk et al, Cancer 2017




Evolution of the Revolution ...



Integration of TUMOR BIOLOGY into







		2023 FIGO staging ³		Molec	cular classification*			
			POLEmei	SEMIRE	NSMP tam-grade+Ellpox	NXMP high-grade #Harg**	g#Jake	
ŝ.	Carboni	i to the allocine corpus						
EA	141	3.ew-grade codenersial. Resid to polypicadorection tre reports sign	Man POC First		8	1441	10 million (10 million)	
	442	Law-grade contemptional, measurements -50%, no focal LVR	Lin POCEssa			1.771	IL HOURS IN THE	
-	14.1	Low-gride endoratively commons of the endorativen & overy?	LAm/WXElima				and the second se	
0		Leevends and enderstatisid, an any axion 250%, notical LVSI	ENG POLEMA		12	1941	THUR DOWN	
Ċ.		ikgh-grade histologies", lexited to polyvice be of itali-	EAst POLEman		Hite			
(Confined	to the eterns	1					
in.		Low-grade understantist, invesion of the converse smooth	LAm POLEura			100 C	- HEIALINDIAAN	
IR .	1	Low-guda enternettoid, subtractal LVSI***	LAM PERSING	and the second second second second	1	1.443	III. moliline	
IC.		High-grade histologies", mynimumion	LNN POLEnst LNN POLEsta	Microsoft <50%, no Deg UVS Microsoft =50%, no Deg UVS	8.6		HCropSides	
			IAm FOXEbeat	Certain monot income, surfaced LVM				
	Treation	den registed spread	Unit POCEERSE.	Subdated LVSP*				
IIA .	IEA/	Spread to every of fillopian table inways when mosting stage DA3 error and	1		ř I		1	
and a			-					
1.1	IEA2	her elvenest of use he subserves or spread through the overing serves	-					Diele Creatine
110	III51	Metastasia or direct spread to the rights and/or the parametria						Risk Groups
	IIIC	Abitadatie to the polyar pactoration						
uit:	HIC1	Schrie lyngfe node metaniscie						
	ADC14	Metoretation					A REPORT OF A R	Low risk
	HICTO.	Macroractastanis	2				5	
	HIC2.	Para-conto Symph male metamates (ap to send vessels)	1					
	HICD .	Microsoftenante	2		1			Internet address where
	IIICDi	Macoverctuation					(and the second se	Intermediate risk
IK .	Locale a	thancel and or metastatic docare			5 · · · · · · · · · · · · · · · · · · ·		1	
NA:	1	for mean of the reasons under the tetrated reasons	2	1			1 A A A A A A A A A A A A A A A A A A A	
	Mailain	to discuss or eventual phones effect surgery						High-intermediate
iitus.		With Oral and Design						
nn	-	Annual resident incentific pits						
11		- discussion and a second			1 E		1 41	High risk

Green denotes low risk for recurrence; yellow denotes intermediate risk, orange denotes high-intermediate risk and red denotes high risk; grey denotes uncertain risk classification because of lack of data.

T 2023 FIGO staging: when molecular classification is known, the FIGO stage should be reported with an annotation of in (for molecular) followed by the specific molecular subtype. There are two specific molecularly defined FIGO stages, namely stage IAm POLEmmi stages I and II disease with a pathogenic POLE mutation) and stage IICm p53abn (stages I and II disease with a p53 abnormality and myometrial invasion), (these two molecularly defined FIGO stages are indicated in the table's cells)

*Details on determining the molecular classification, including allocation for double classifiers, are detailed in figure 2 and the webappendix, pp 18-20.

**The molecular subgroup NSMP high-grade-ERseg consists of either high-grade NSMP cases or ERseg NSMP cases. Thus, in FIGO stages referring to invegrate endometrioid carcinomus (i.e. IA1, IA2, IA3, IB, IIA and IID) only to the ERseg cases of the molecular subgroup NSMP high-grade ERseg apply.

***Substantial LVSI is defined according to WHO criteria by 24 vessels in at least one H&E slide (refer to appendix for information on LVSI, pp 18-20).

myoinvasion <50% + no/focal LVSI + ovarian tamour pT1a


'High-grade histologies are the FIGO 2023 aggressive histolypes that include high-grade andometroid (grade 3), senses, clear call carcinomas, circlinosarcomas, undifferentiated, mixed, mesonephric-like, and gastrointential macinous type carcinoma.

XXII ASSEMBLEA MaNGO | STANDARD TREATMENTS AND NEW DIRECTIONS IN GYNAECOLOGICAL CANCERS MILANO 26th-27th-28th June 2025




Uncertain, lack of data

Verification of the prognostic precision of the new 2023 FIGO staging system in endometrial cancer patients – an international pooled analysis of three ESGO accredited centers





Verification of the prognostic precision of the new 2023 FIGO staging system in endometrial cancer patients – *an international pooled analysis of three ESGO accredited centers*



Progression-free survival in a study cohort of 232 endometrial cancer patients according to

Statistical tests demonstrated superiority of 2023 FIGO staging system compared to 2009 to predict PFS and OS

> Schwameis R et al, Eur J Cancer 2023 Editorial by Vergote I & Matias-Guiu X, Eur J Cancer 2023



MaNGO



(remelli

MELEZINGSCHI LANIVILISTIÄT







<u>Prognostic risks</u> in the respective groups are defined as estimated overall 5-year risk of recurrence:

• low risk group:	risk less than 8%;
 intermediate risk group: 	risk between 8 and 15%;
 high-intermediate risk group: 	risk between 15 and 25%;
 high risk group: 	risk higher than 25%.





	2023 FIGO staging [™]		Molecular classification					
			POLEmut	MMRd	NSMP low- grade+ERpos	NSMP high- grade/ERneg*	p53abn	
I	Conf	ined to the uterine corpus				•	• ·	
IA	IA1	Low-grade endometrioid, limited to polyp/endometrium (no myoinvasion)	IAm POLEmut					
	IA2	Low-grade endometrioid, myoinvasion <50%, no/focal LVSI	IAm POLEmut					
0	IA3	Low-grade endometrioid carcinoma of the endometrium & ovary#						
в		Low-grade endometrioid, myoinvasion ≥50%, no/focal LVSI	IAm POLEmut					
IC		High-grade histologies^, limited to polyp/endometrium	IAm POLEmut					

Green denotes low risk for recurrence.

 π 2023 FIGO staging: when molecular classification is known, the FIGO stage should be reported with an annotation of m (for molecular) followed by the specific molecular subtype. There are two specific molecularly defined FIGO stages, namely stage IAm *POLE*mut (stages I and II disease with a pathogenic *POLE* mutation) and stage IICm p53abn (stages I and II disease with a p53 abnormality and myometrial invasion).

*The molecular subgroup NSMP high-grade/ERneg consists of either high-grade NSMP cases or ERneg NSMP cases. Thus, in FIGO stages referring to *low-grade* endometrioid carcinomas (i.e. IA1, IA2, IA3, IB, IIA and IIB) only to the ERneg cases of the molecular subgroup NSMP high-grade/ERneg apply.

nryoinvasion <50% + no/focal LVSI + ovarian tumour pT1a</p>

^High-grade histologies are the FIGO 2023 aggressive histotypes that include high-grade endometrioid (grade 3), serous, clear cell carcinomas, carcinosarcomas, undifferentiated, mixed, mesonephric-like, and gastrointestinal mucinous type carcinoma.





	2022 EICO staring	Molecular classification					
2023 FIGO staging [™]		POLEmut	MMRd	NSMP low- grade+ERpos	NSMP high- grade/ERneg*	p53abn	
п	Confined to the uterus						
IIA	Low-grade endometrioid, invasion of the cervical stroma	IAm POLEmut					
IIB	Low-grade endometrioid, substantial LVSI**	IAm POLEmut					
IIC	High-grade histologies^, myoinvasion	IAm POLEmut		5 A	.:		

Green denotes low risk for recurrence.

 π 2023 FIGO staging, when molecular classification is known, the FIGO stage should be reported with an annotation of m (for molecular) followed by the specific molecular subtype. There are two specific molecularly defined FIGO stages, namely stage IAm *POLE*mut (stages I and II disease with a pathogenic *POLE* mutation) and stage IICm p53abn (stages I and II disease with a p53 abnormality and myometrial invasion). These two molecularly defined FIGO stages are indicated in the table's cells.

*The molecular subgroup NSMP high-grade/ERneg consists of either high-grade NSMP cases or ERneg NSMP cases. Thus, in FIGO stages referring to *low-grade* endometrioid carcinomas (i.e. IA1, IA2, IA3, IB, IIA and IIB) only to the ERneg cases of the molecular subgroup NSMP high-grade/ERneg apply.

**Substantial LVSI is defined according to WHO criteria in at least one H&E slide.


'High-grade histologies are the FIGO 2023 aggressive histotypes that include high-grade endometrioid (grade 3), serous, clear cell carcinomas, carcinosarcomas, undifferentiated, mixed, mesonephric-like, and gastrointestinal mucinous type carcinoma.



ADJUVANT THERAPY LOW RISK



For patients with low-risk EC: no adjuvant therapy is recommended [II, A].









		2023 FIGO staging [™]	Molecular classification				
			POLEmut	MMRd	NSMP low- grade+ERpos	NSMP high- grade/ERneg*	p53abn
Ι	Conf	ined to the uterine corpus		л н	- 1	·	
IA	IA1	Low-grade endometrioid, limited to polyp/endometrium (no myoinvasion)	IAm POLEmut	2		*	
	IA2	Low-grade endometrioid, myoinvasion <50%, no/focal LVSI	IAm POLEmut			*	IICm p53abn
1	IA3	Low-grade endometrioid carcinoma of the endometrium & ovary#				*	
B		Low-grade endometrioid, myoinvasion ≥50%, no/focal LVSI	IAm POLEmut	с с		*	IICm p53abn
IC		High-grade histologies^, limited to polyp/endometrium	IAm POLEmut		n.a.		

Grey denotes uncertain risk classification because of lack of data.

 π 2023 FIGO staging: when molecular classification is known, the FIGO stage should be reported with an annotation of m (for molecular) followed by the specific molecular subtype. There are two specific molecularly defined FIGO stages, namely stage IAm *POLE*mut (stages I and II disease with a pathogenic *POLE* mutation) and stage IICm p53abn (stages I and II disease with a p53 abnormality and myometrial invasion). These two molecularly defined FIGO stages are indicated in the table's cells.

*The molecular subgroup NSMP high-grade/ERneg consists of either high-grade NSMP cases or ERneg NSMP cases. Thus, in FIGO stages referring to *low-grade* endometrioid carcinomas (i.e. IA1, IA2, IA3, IB, IIA and IIB) only to the ERneg cases of the molecular subgroup NSMP high-grade/ERneg apply.

nryoinvasion <50% + no/focal LVSI + ovarian tumour pT1a

*High-grade histologies are the FIGO 2023 aggressive histotypes that include high-grade endometrioid (grade 3), serous, clear cell carcinomas, carcinosarcomas, undifferentiated, mixed, mesonephric-like, and gastrointestinal mucinous type carcinoma.





ADJUVANT THERAPY FIGO 2023 IA1m NSMP high-grade/ERneg or p53abn & ICm NSMP high-grade/Erneg or p53abn

 There are limited data suggesting that the risk of recurrence is somewhat higher than for low-risk carcinomas. However, adjuvant therapy is generally not recommended [IV, C].





<u>Prognostic risks</u> in the respective groups are defined as estimated overall 5-year risk of recurrence:

•	low risk group	risk less than 8%
•	intermediate risk group:	risk between 8 and 15%;
•	high-intermediate risk group:	risk between 15 and 25%;
•	high risk group:	risk higher than 25%.







	2023 FIGO staging [™]		Molecular classification						
			POLEmut	MMRd	NSMP low- grade+ERpos	NSMP high- grade/ERneg*	p53abn		
I	Conf	ined to the uterine corpus							
IA	IA1	Low-grade endometrioid, limited to polyp/endometrium (no myoinvasion)			2		-3		
	IA2	Low-grade endometrioid, myoinvasion <50%, no/focal LVSI							
	IA3	Low-grade endometrioid carcinoma of the endometrium & ovary#			0	5			
IB		Low-grade endometrioid, myoinvasion ≥50%, no/focal LVSI							
IC		High-grade histologies^, limited to polyp/endometrium			0	2			

Yellow denotes intermediate risk for recurrence.

T 2023 FIGO staging: when molecular classification is known, the FIGO stage should be reported with an annotation of m (for molecular) followed by the specific molecular subtype. There are two specific molecularly defined FIGO stages, namely stage IAm POLEmut (stages I and II disease with a pathogenic POLE mutation) and stage IICm p53abn (stages I and II disease with a p53 abnormality and myometrial invasion).

*The molecular subgroup NSMP high-grade/ERneg consists of either high-grade NSMP cases or ERneg NSMP cases. Thus, in FIGO stages referring to low-grade endometrioid carcinomas (i.e. IA1, IA2, IA3, IB, IIA and IIB) only to the ERneg cases of the molecular subgroup NSMP high-grade/ERneg apply.

nryoinvasion <50% + no/focal LVSI + ovarian tumour pT1a

"High-grade histologies are the FIGO 2023 aggressive histotypes that include high-grade endometrioid (grade 3), serous, clear cell carcinomas, carcinosarcomas, undifferentiated, mixed, mesonephric-like, and gastrointestinal mucinous type carcinoma.







	2022 FICO stashed	Molecular classification							
	2023 FIGO staging [*]	POLEmut	MMRd	NSMP low- grade+ERpos	NSMP high- grade/ERneg*	p53abn			
П	Confined to the uterus		•						
IIA	Low-grade endometrioid, invasion of the cervical stroma		25		5 2	5			
IB	Low-grade endometrioid, substantial LVSI**		. *	2					
IIC	High-grade histologies^, myoinvasion		Myoinvasion <50%, no/focal LVSI	7		2			
			Myoinvasion ≥50%, no/focal LVSI	<u>_</u>					
				1	5	5			

Yellow denotes intermediate risk for recurrence.

π 2023 FIGO staging: when molecular classification is known, the FIGO stage should be reported with an annotation of m (for molecular) followed by the specific molecular subtype. There are two specific molecularly defined FIGO stages, namely stage IAm *POLE*mut (stages I and II disease with a pathogenic *POLE* mutation) and stage IICm p53abn (stages I and II disease with a p53 abnormality and myometrial invasion). These two molecularly defined FIGO stages are indicated in the table's cells.

*The molecular subgroup NSMP high-grade/ERneg consists of either high-grade NSMP cases or ERneg NSMP cases. Thus, in FIGO stages referring to *low-grade* endometrioid carcinomas (i.e. IA1, IA2, IA3, IB, IIA and IIB) only to the ERneg cases of the molecular subgroup NSMP high-grade/ERneg apply.

**Substantial LVSI is defined according to WHO criteria in at least one H&E slide.


^High-grade histologies are the FIGO 2023 aggressive histotypes that include high-grade endometrioid (grade 3), serous, clear cell carcinomas, carcinosarcomas, undifferentiated, mixed, mesonephric-like, and gastrointestinal mucinous type carcinoma.



ADJUVANT THERAPY INTERMEDIATE RISK



- For patients with intermediate risk EC: adjuvant vaginal brachytherapy should be considered [I, A].
- No adjuvant therapy is an option [III, C], especially for patients under 60 years of age and/or low grade [II, A]







<u>Prognostic risks</u> in the respective groups are defined as estimated overall 5-year risk of recurrence:

 low risk group: 	risk less than 8%;
 intermediate risk group; 	risk between 8 and 15%;
 high-intermediate risk group: 	risk between 15 and 25%;
 high risk group: 	risk higher than 25%.





	2022 FICO staring	Molecular classification							
	2023 FIGO staging [®]	POLEmut	MMRd	NSMP low- grade+ERpos	NSMP high- grade/ERneg*	p53abn			
П	Confined to the uterus			· · ·	·				
IIA	Low-grade endometrioid, invasion of the cervical stroma								
IIB	Low-grade endometrioid, substantial LVSI**					80 90			
IIC	High-grade histologies^, myoinvasion				•	~			
			Cervical stromal invasion, no/focal LVSI Substantial LVSI*						

Orange denotes high-intermediate risk for recurrence.

 π 2023 FIGO staging: when molecular classification is known, the FIGO stage should be reported with an annotation of m (for molecular) followed by the specific molecular subtype. There are two specific molecularly defined FIGO stages, namely stage IAm *POLE*mut (stages I and II disease with a pathogenic *POLE* mutation) and stage IICm p53abn (stages I and II disease with a p53 abnormality and myometrial invasion). These two molecularly defined FIGO stages are indicated in the table's cells.

*The molecular subgroup NSMP high-grade/ERneg consists of either high-grade NSMP cases or ERneg NSMP cases. Thus, in FIGO stages referring to *low-grade* endometrioid carcinomas (i.e. IA1, IA2, IA3, IB, IIA and IIB) only to the ERneg cases of the molecular subgroup NSMP high-grade/ERneg apply.

**Substantial LVSI is defined according to WHO criteria in at least one H&E slide.


"High-grade histologies are the FIGO 2023 aggressive histotypes that include high-grade endometrioid (grade 3), serous, clear cell carcinomas, carcinosarcomas, undifferentiated, mixed, mesonephric-like, and gastrointestinal mucinous type carcinoma.



ADJUVANT THERAPY HIGH-INTERMEDIATE RISK



- For patients with high-intermediate-risk EC: adjuvant EBRT is recommended for optimal pelvic control [II, A].
- Vaginal brachytherapy is an alternative option, especially for patients who underwent lymph node staging and are pN0 [II, B].
- No adjuvant therapy can be considered, especially for patients who underwent lymph node staging and are pNO, without substantial LVSI and low-grade disease [IV, B].








<u>Prognostic risks</u> in the respective groups are defined as estimated overall 5-year risk of recurrence:

 low risk group: 	risk less than 8%;
 intermediate risk group: 	risk between 8 and 15%;
 high-intermediate risk group: 	risk between 15 and 25%:
 high risk group: 	risk higher than 25%.







Red denotes high risk for recurrence.

 π 2023 FIGO staging: when molecular classification is known, the FIGO stage should be reported with an annotation of m (for molecular) followed by the specific molecular subtype. There are two specific molecularly defined FIGO stages, namely stage IAm *POLE*mut (stages I and II disease with a pathogenic *POLE* mutation) and stage IICm p53abn (stages I and II disease with a p53 abnormality and myometrial invasion).

*The molecular subgroup NSMP high-grade/ERneg consists of either high-grade NSMP cases or ERneg NSMP cases. Thus, in FIGO stages referring to *low-grade* endometrioid carcinomas (i.e. IA1, IA2, IA3, IB, IIA and IIB) only to the ERneg cases of the molecular subgroup NSMP high-grade/ERneg apply.

nryoinvasion <50% + no/focal LVSI + ovarian tumour pT1a

*High-grade histologies are the FIGO 2023 aggressive histotypes that include high-grade endometrioid (grade 3), serous, clear cell carcinomas, carcinosarcomas, undifferentiated, mixed, mesonephric-like, and gastrointestinal mucinous type carcinoma.





Low	Intermediate	High- Intermediate	High	Uncertai	in			Gyna	ecological Oncolog
							Molecular classifie	cation*	
					POLE mut	MMRd	NSMP low- grade+ERpos	NSMP high- grade/ERneg**	p53abn
Local and	/or regional spre	ad beyond uter	us						
1	Spread to ovary o	r fallopian tube	(except for #)		IIIA1	IIIA1	IIIA1	IIIA1	IIIA1
1	Involvement of uterine subserosa or spread through the			IIIA2	IIIA2	IIIA2	IIIA2	IIIA2	
1	uterine serosa								
	Metastasis or dire parametrium	ect spread to the	vagina and/or	the	IIIB	IIIB	IIIB	IIIB	IIIB
	Metastasis to the	pelvic peritoneu	m		IIIB2	IIIB2	IIIB2	IIIB2	IIIB2
	Metastasis to the	• •			IIIC1	IIIC1	IIIC1	IIIC1	IIIC1
]	Metastasis to the	para-aortic lym	oh nodes		IIIC2	IIIC2	IIIC2	IIIC2	IIIC2
Locally ad	lvanced								
Invasion of	f bladder mucosa	and/or intestina	l mucosa		IVA	IVA	IVA	IVA	IVA
Low-grad	e endometrioid o	arcinoma of bo	oth the endom	netrium					
+ ovary #									
Myoinvasive <50%, no/focal LVSI, ovarian tumour pT1a				IA3	IA3	IA3	IA3**	IA3	


112.00



ADJUVANT THERAPY HIGH RISK




- For patients with high risk EC: EBRT with concurrent and adjuvant chemotherapy [I, A].
- or alternatively sequential chemotherapy and radiotherapy are recommended [I, B].
- Chemotherapy ± brachytherapy is an alternative option [I, B].
- For patients with FIGO 2023 stage IIIm-IVAm MMRd EC, adjuvant chemotherapy combined with an ICI (± EBRT) should be considered [II, B].





ENGOT-EN11/GOG-3053/KEYNOTE-B21 Study Design



*Chemotherapy was administered for 4 cycles in patients planned to receive chemoradiotherapy and 6 cycles for all other patients, including those planned for radiotherapy without radiosensitizing cisplatin. *Radiotherapy was optional at the discretion of the investigator, and cisplatin may have been given with EBRT as radiosensitizer; radiotherapy was started within 6 weeks after completion of carboplatin and paclitaxel (radiation may have been initiated during Stage 1 or Stage 2 depending on the number of cycles of chemotherapy that were administered).

T. Van Gorp et al. Annals of Oncology, 2024





ADJUVANT THERAPY FIGO 2023 STAGES IIImPOLE_{mut} and IVAm POLE_{mut}

- This part includes the following categories:
 - FIGO 2023 stages IIImPOLEmut
 - FIGO 2023 stage IVAm POLEmut





ADJUVANT THERAPY FIGO 2023 STAGES IIImPOLE_{mut} and IVAm POLE_{mut}

 For patients with FIGO 2023 stage IIIm POLEmut and IVAm POLEmut (prognostic risk group allocation is unclear) due to limited number of patients no firm treatment recommendations can be given, however, following a case-by-case multidisciplinary team discussion, de-escalation from high-risk treatment can be considered [IV, B].



KEY CHANGES

EARLY stage disease: stage I/II


- degree of LVSI (no/focal vs substantial)
- histological subtypes and grading (low-grade endometroid vs high-grade (aggressive) histological types)
- Molecular classification, if available

ADVANCED stage disease: stage I/II

- Metastatic spread to the ovary: Distinction of low-grade endometrioid carcinoma involving the endometrium and the ovary
- Refinement of of lymph node metastasis (micro- vs macrometastasis)
- New evaluation of peritoneal carcinomatosis







WHO definition

Extent of LVSI is important


- Focal LVSI is defined by the presence of a single focus around the tumor
- Substantial LVSI as multifocal or diffuse arrangement of LVSI or the presence of tumor cells ≥ 5 lymphovascular spaces.



ESGO-ESTRO-ECP consensus guideline on LVSI

- Substantial LVSI is robust and shows <u>consistent prognostic results</u>, supporting the continues use as critical risk factor.
- Studying optimal threshold for altering clinical management remains complex, but most current studies recommend 4 vessels.
- Data on focal LVSI are not consistent (for understandable reasons). Present <u>data</u> <u>insufficient</u> to recommend differential treatment based on focal LVSI. <parallel with ITC discussion; report it, but don't act on>
- Prospective data on focal LVSI are eagerly awaited, ideally in the setting of molecularly classified stage I EC (PORTEC4a)







KEY CHANGES

EARLY stage disease: stage I/II

- degree of LVSI (no/focal vs substantial)
- histological subtypes and grading (low-grade endometroid vs aggressive histological types)
- Molecular classification, if available

ADVANCED stage disease

- Metastatic spread to the ovary: Distinction of low-grade endometrioid carcinoma involving the endometrium and the ovary
- Refinement of of lymph node metastasis (micro- vs macrometastasis)
- New evaluation of peritoneal carcinomatosis



low-grade endometrioid carcinoma involving the endometrium & the ovary ("synchronous tumors")

molecular analysis: most of them are clonal (metastatic)

GOOD PROGNOSIS

 \checkmark When all the following criteria need to be met:

according to WHO:

- (1) no more than superficial myometrial invasion is present (<50%)
- (2) the absence of substantial LVSI
- (3) the absence of additional metastases

according to ESGO-ESTO-ESP Guidelines, in addition

(4) unilateral **ovarian tumors**, limited to the ovary, without capsule invasion/rupture (equivalent to **pT1a**)



KEY CHANGES

EARLY stage disease: stage I/II

- degree of LVSI (no/focal vs substantial)
- histological subtypes and grading (low-grade endometroid vs aggressive histological types)
- Molecular classification, if available


ADVANCED stage disease: stage I/II

- Metastatic spred to the ovary: Distinction of low-grade endometrioid carcinoma involving the endometrium and the ovary
- Refinement of of lymph node metastasis (micro- vs macrometastasis)
- New evaluation of peritoneal carcinomatosis



Application of FIGO 2023 staging criteria to patients with "previous FIGO 2009 IVB" EC

2009 FIGO IVB, n=88, Ohio State University Wexner Medical Center



<u>Conclusion:</u> The 2023 FIGO staging criteria significantly improves our ability to risk-stratify patients.

Haight et al, Gynecol Oncol 2023 Sept

XXII ASSEMBLEA MaNGO | STANDARD TREATMENTS AND NEW DIRECTIONS IN GYNAECOLOGICAL CANCERS MILANO 26th-27th-28th June 2025




The right time for change: A report on the heterogeneity of IVB endometrial cancer and improved risk-stratification provided by new 2023 FIGO staging criteria




Paulina J. Haight *, Courtney J. Riedinger, Floor J. Backes, David M. O'Malley, Casey M. Cosgrove over a Gravinge Unitige Imperiant of Neurona and Generality. To this Steenberry's Weeker Media Dave, Depart Caser Angel and Second Seco

OS stage IVB FIGO 2009



OS same cohort FIGO 2023








What's new for Advanced/Recurrent Setting?



First line systemic therapy in unresectable stage III-IV or recurrent endometrial carcinoma with no prior chemotherapy except in the adjuvant setting (including patients with residual disease after surgery)



XXII ASSEMBLEA MaNGO | STANDARD TREATMENTS AND NEW DIRECTIONS IN GYNAECOLOGICAL CANCERS MILANO 26th-27th-28th June 2025



18

European Society of






FIRST LINE SYSTEMIC THERAPY

in unresectable stage III/IV or recurrent EC with no prior chemotherapy except in the adjuvant setting (including patients with residual disease after surgery)

 The MMR status should be taken into consideration to determine the choice of first line therapy:

Patients with MMRd tumours should be offered an ICI e.g. dostarlimab or durvalumab or pembrolizumab (drugs mentioned in alphabetical order) in combination with carboplatin-paclitaxel chemotherapy followed by ICI as maintenance therapy [I, A].










FIRST LINE SYSTEMIC THERAPY

in unresectable stage III/IV or recurrent EC with no prior chemotherapy except in the adjuvant setting (including patients with residual disease after surgery)

Patients with non-MMRd tumours with rapidly growing/symptomatic disease should be offered carboplatin- paclitaxel chemotherapy [I, A]. The addition of ICI to chemotherapy followed by ICI as maintenance therapy, e.g. dostarlimab or pembrolizumab (drugs mentioned in alphabetical order), or the addition of ICI followed by a combination of ICI and PARPi as maintenance therapy, i.e. durvalumab and olaparib, can be considered [I, B].









FIRST LINE SYSTEMIC THERAPY


in unresectable stage III/IV or recurrent EC with no prior chemotherapy except in the adjuvant setting (including patients with residual disease after surgery)

If chemotherapy is contraindicated, in patients with non-MMRd relapsed disease and with prior chemotherapy in the adjuvant/neoadjuvant setting, a combination of pembrolizumab and the multi-tyrosine-kinase inhibitor lenvatinib may be considered [III, C].



ENGOT-en9/LEAP-001 Progression-Free Survival^a Improved With LEN/PEMBRO vs TC in Prior Neoadjuvant/Adjuvant Chemotherapy Subgroup European Society of









FIRST LINE SYSTEMIC THERAPY


in unresectable stage III/IV or recurrent EC with no prior chemotherapy except in the adjuvant setting (including patients with residual disease after surgery)

- If ICI (± PARPi) is contraindicated, for patients with a HER2 3+ tumour, a combination of carboplatin-paclitaxel plus trastuzumab may be considered [II, B].
- The standard chemotherapy regimen is 6 cycles of carboplatinpaclitaxel [I, A].





Carboplatin/paclitaxel+/-Trastuzumab (NCT01367002) Updated Survival analysis stage III/IV



In a subset analysis of pts restricted to stage IIIC/IV disease, the addition of trastuzumab (n=17) continued to provide both (*left*) PFS benefit over control (n=19) and OS benefit over control (21.1 versus 31.9 months, HR 0.440 90% CI 0.219-0.882 p=0.0230).





FIRST LINE SYSTEMIC THERAPY

in unresectable stage III/IV or recurrent EC with no prior chemotherapy except in the adjuvant setting (including patients with residual disease after surgery)

- In low-grade ER-positive, low volume/asymptomatic advanced or slowly growing recurrent tumours, endocrine therapy is the preferred systemic therapy:
 - Progestins (medroxyprogesterone acetate or megestrol acetate) are recommended [III, A].
 - Alternative options include aromatases inhibitors, and tamoxifen [IV, C].



Open Questions...

232

- > Are all POLE variants qualified as POLEmut EC?
- > Which is the cut-off to define HR positive status in EC?
- > Which is the prognostic role of focal LVSI? Which is the optimal clinical threshold?
- > How to consider EC confined to polyp/endometrium with no myoinvasion?
- ➤ How to treat stage III/IVA POLEmut EC?
- > Which is the best treatment option for advanced/recurrent non dMMR EC?



Take Home Messages

- New Endometrial Cancer FIGO staging system integrates tumor biology/molecular classification
- New FIGO staging system identifies treatment-relevant groups in order to customize the medical strategy for our patients
- > There are still some 'grey areas' which need further investigation
- In advanced/recurrent setting immune-checkpoint inhibitors are paving the present and the future of EC

THE NEW FIGO CLASSIFICATION HAS COMPLETELY CHANGE THE MEDICAL PERSPECTIVE ON ENDOMETRIAL CANCER AND WE ARE STILL LEARNING..





